sandoz-logo.jpg
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
January 23, 2023 18:30 ET | Novartis Pharma AG
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly...
Valo Tx Logo.jpg
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
January 11, 2023 02:00 ET | Valo Therapeutics LTD
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it...
Icosavax_Logo.jpg
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
January 06, 2023 08:00 ET | Icosavax, Inc.
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of...
Logo.png
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
January 05, 2023 08:30 ET | Imunon, Inc.
LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and The Wistar Institute, a global leader in...
ibn-iw-globe-2.png
IBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
December 13, 2022 08:17 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to...
New Logo.png
Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
December 12, 2022 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s Board of Directors (Board) has decided to not undertake the reverse stock split and...
BiondVax LOGO.png
BiondVax Regains Nasdaq Compliance
December 12, 2022 07:06 ET | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...
BioGX Launches 'pixl™' Portable qPCR Platform Ex-US With Expanded Test Menu for Infectious Diseases
December 08, 2022 14:00 ET | BioGX Inc.
BIRMINGHAM, Ala., Dec. 08, 2022 (GLOBE NEWSWIRE) -- BioGX, a global provider of easy molecular diagnostic solutions since 2007, announced the Ex-US commercial release of its portable pixl™ qPCR...
ARIDIS_LOGO.png
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
November 22, 2022 09:10 ET | Aridis Pharmaceuticals, Inc.
The Company’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 ...
Meticulous Logo.png
Point-of-Care Diagnostics Market Worth $82.74 Billion by 2029 - Exclusive Report by Meticulous Research®
November 22, 2022 09:00 ET | Meticulous Market Research Pvt. Ltd.
Redding, California, Nov. 22, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled, ‘Point-of-Care Diagnostics Market by Application (Influenza, Pneumonia, COVID-19, TB, HAI,...